UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2024
Commission File Number 001-41923
EUPRAXIA PHARMACEUTICALS INC.
(Exact name of Registrant as specified in its charter)
N/A
(Translation of Registrants name)
201-2067 Cadboro Bay Road
Victoria, British Columbia, Canada V8R 5G4
Telephone: (250) 590-3968
(Address and telephone number of registrants principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☐ Form 40-F ☒
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Eupraxia Pharmaceuticals Inc.
| ||||||
Date: March 15, 2024 | By: | /s/ Bruce Cousins | ||||
Name: Bruce Cousins | ||||||
Title: President and Chief Financial Officer |
Exhibit 99.1
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES
Eupraxia Pharmaceuticals Announces Closing of Overnight Marketed Offering for Gross Proceeds of C$33.9 Million
VICTORIA, British ColumbiaMarch 15, 2024 - Eupraxia Pharmaceuticals Inc. (Eupraxia or the Company) (TSX: EPRX), a clinical-stage biotechnology company, today announced that it has closed its previously announced overnight marketed public offering (the Offering) of common shares of the Company (the Shares). Pursuant to the Offering, Eupraxia issued 8,260,435 Shares at a price of C$4.10 per Share for gross proceeds of C$33,867,784, which includes the issuance of 943,435 Shares upon exercise of the over-allotment option.
Eupraxia expects to use the net proceeds of the Offering, together with its existing cash and cash equivalents, primarily to fund research and development activities, general and administrative expenses, a milestone payment, working capital needs and other general corporate purposes.
The Common Shares were offered pursuant to a final prospectus supplement dated March 12, 2024 to the Companys short form base shelf prospectus dated February 5, 2024. The Common Shares were offered in each of the provinces of Canada, except Québec.
Raymond James Ltd. acted as sole underwriter and bookrunner for the Offering.
No securities regulatory authority has either approved or disapproved the contents of this press release. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the common shares in the United States or in any province, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such province, state or jurisdiction. The securities have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements thereunder. The Company does not intend to register any part of the Offering in the United States, and any public offering of securities to be made in the United States will only be made by means of a prospectus that may be obtained from the issuer and that will contain detailed information about the Company and management, as well as financial statements.
About Eupraxia Pharmaceuticals Inc.
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. The Company strives to provide improved patient benefit and has developed technology designed to deliver targeted, long-lasting activity with fewer side effects.
Notice Regarding Forward-Looking Statements and Information
This press release includes forward-looking statements and forwardlooking information within the meaning of applicable securities laws. Often, but not always, forwardlooking information can be identified by the use of words such as plans, is expected, expects, scheduled, intends, contemplates, anticipates, believes, proposes, estimates, potential or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results may, could, would, might or will be taken, occur or be achieved. Forward looking statements in this press release include statements regarding the use of the proceeds of the Offering and the business of the Company.
Such statements and information are based on the current expectations of Eupraxias management, and are based on assumptions, including but not limited to: future research and development plans for the Company proceeding substantially as currently envisioned; industry growth trends, including with respect to projected and actual industry sales; the Companys ability to obtain positive results from the Companys research and development activities, including clinical trials; and the Companys ability to protect patents and proprietary rights. Although Eupraxias management believes that the assumptions underlying these statements and information are reasonable, they may prove to be incorrect. The forwardlooking events and circumstances discussed in this press release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Eupraxia, including, but not limited to: risks and uncertainties related to the Companys limited operating history; the Companys novel technology with uncertain market acceptance; if the Company breaches any of the agreements under which it licenses rights to its product candidates or technology from third parties, the Company could lose license rights that are important to its business; the Companys current license agreement may not provide an adequate remedy for its breach by the licensor; the Companys technology may not be successful for its intended use; the Companys future technology will require regulatory approval, which is costly and the Company may not be able to obtain it; the Company may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications; the Companys clinical trials may fail to demonstrate adequately the safety and efficacy of our product candidates at any stage of clinical development; the Company may be required to suspend or discontinue clinical trials due to side effects or other safety risks; the Company completely relies on third parties to provide supplies and inputs required for its products and services; the Company relies on external contract research organizations to provide clinical and non-clinical research services; the Company may not be able to successfully execute its business strategy; the Company will require additional financing, which may not be available; any therapeutics the Company develops will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the Companys ability to obtain regulatory approval in a timely manner, or at all; the impact of health pandemics or epidemics on the Companys operations; the Companys restatement of its consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on the Companys common share price; and other risks and uncertainties described in more detail in Eupraxias public filings on SEDAR+ (sedarplus.ca). Although Eupraxia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forwardlooking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forwardlooking statement or information can be guaranteed. Except as required by applicable securities laws, forwardlooking statements and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any forwardlooking statement or information, whether as a result of new information, future events or otherwise.
-2-
For investor and media inquiries, please contact:
Danielle Egan, Eupraxia Pharmaceuticals Inc.
778.401.3302
degan@eupraxiapharma.com
or
Adam Peeler, on behalf of:
Eupraxia Pharmaceuticals Inc.
416.427.1235
adam.peeler@loderockadvisors.com
Source: Eupraxia Pharmaceuticals Inc.
-3-
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